Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Medication</td><td class="align_center">Dose</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left"> Sorafenib</td><td class="align_center">200 mg by mouth twice daily</td></tr><tr><td class="align_left">Carvedilol</td><td class="align_center">3.125 mg by mouth twice daily</td></tr><tr><td class="align_left">Furosemide</td><td class="align_center">80 mg by mouth twice daily</td></tr><tr><td class="align_left">Lisinopril</td><td class="align_center">10 mg by mouth daily</td></tr><tr><td class="align_left">Aspirin</td><td class="align_center">81 mg by mouth daily</td></tr><tr><td class="align_left">Warfarin</td><td class="align_center">2.5 mg by mouth daily</td></tr><tr><td class="align_left">Nitroglycerin</td><td class="align_center">0.4 mg sublingual as needed</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Case Reports in Cardiology

tab1

Table 1

Table 1: Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion 

Table 1 | Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion 